Nobio News
7 articles
Nobio's infinix™ Antibacterial Composites Recognized as a 2021 Best of Class Technology Award Winner
Nobio Ltd., the inventor of FDA cleared antibacterial composites, has been recognized as a 2021 Best of Class Technology Award winner for its infinix line of advanced restorative materials. The award highlights the clinical importance of infinix in preventing demineralization and reducing restoration failure due to secondary caries. The infinix line includes various composites and a bonding system, all incorporating Nobios patented antimicrobial particle technology. The recognition from the panel of thought-leading clinicians signifies the promise of the Nobio platform. Nobio is a material sciences company that aims to bring long-lasting antimicrobial properties to a wide range of products and applications. The article does not mention any specific partners, investors, customers, or financial details.
Partners
Nobio's Antibacterial Composites Receive FDA 510(k) Clearance for Addressing a Key Process in Tooth Decay
Nobio Ltd. has received FDA 510(k) clearance for its Infinix family of dental composites. Clinical data showed that the composites significantly reduce tooth demineralization, a key process in tooth decay. The composites incorporate Nobios patented QASiTM particle technology, which inhibits bacterial growth at the margins of composite fillings. The company plans to initiate commercial sales of the Infinix product line by the end of the year. The article highlights the potential for Infinix to reduce recurrent decay, improve restoration longevity, and minimize natural tooth loss. The FDA clearance validates the technology and its potential impact on restorative dentistry.
Customers
Nobio Secures Grant From the Israel Innovation Authority for Protective Measures Against Covid-19
Nobio Ltd. has received a grant from the Israel Innovation Authority to develop and manufacture innovative solutions for managing the COVID-19 outbreak. The $205,000 grant will support the development and manufacture of personal protective equipment (PPE) and long-acting surface coating using Nobios antimicrobial technology. The companys Infinix products for dental restorations received FDA clearance last year and will be launched commercially in the second half of 2020. The grant will focus on two applications: antiviral facemasks and nonwoven fabrics for protective wear, as well as surface coatings to prevent transmission of pathogenic microorganisms. Nobio is also scaling up production capacity to meet the expected increase in demand.
Investment
Nobio and Supergum to Prototype and Test Protective Face Masks Against Viruses
Startup Nobio gets FDA nod for antibacterial dental fillings
Israeli startup Nobio Ltd. has received FDA approval to market its antibacterial material for dental fillings. The approval gives Nobio access to the $1.4 billion dental materials market. The company plans to make its products available to dentists through its own brand and through licensing to other manufacturers. Nobio is currently negotiating with distributors and manufacturers for commercial partnerships. The FDA approval also increases the chances of further approvals for the companys technology. Nobio has raised $9 million to date from investors including aMoon Fund and Dr. Ole Jensen.
Customers
Bacteria resistant materials co Nobio raises $3.6m
Israeli company Nobio has raised $3.5 million in a financing round led by aMoon fund and anchor investor Marius Nacht. Nobio develops bacteria-resistant materials for the medical devices and dental health markets. Their lead product is a material for dental fillings that prevents infection. The company plans to obtain marketing approval for this product in 2019 and hopes to include it in a variety of medical devices. Nobios technology integrates bacteria-killing particles within the material using nanotechnology production technology. The investment will enable the company to obtain regulatory approvals and make progress in trials of medical applications.
InvestmentExpand
Germs are no match for NanoLock's antimicrobial nanomaterial
Israeli company NanoLock expects to win regulatory clearance for its first two products embedded with a novel antimicrobial nanomaterial. The nanomaterial, developed by Prof. Ervin Weiss, has the potential to address biofilm-related infections on medical devices. NanoLocks first priority is dental materials, but the company is open to strategic partnerships to expand into other fields. The nanomaterial is unique in that it kills both bacteria and fungi, is built into the device, and contains no metal or toxic ingredients. NanoLock is completing a feasibility study and is looking to complete its first investment round. The company aims to enable the use of medical devices with inherent antimicrobial properties throughout their lifecycle.
PartnersInvestment
